Technology company CureVac has appointed Pierre Kemula as new chief financial officer, a position responsible for overseeing the company’s financial and capital market initiatives.
CureVac was founded in 2000 as a spin-off from the University of Tϋbingen in Germany and develops drugs based on messenger RNA molecules. The company creates cancer immunotherapies and prophylactic vaccines that protect against infectious diseases.
Kemula, a graduate of the London School of Economics in the United Kingdom, will also be joining CureVac’s management board, the company said in a statement. Prior to CureVac, he was CFO at Pixium Vision, a medical technology company specializing in the development of vision devices for blind patients.
"Adding an executive with Pierre's financial and transactional expertise, as well as his global markets experience, is a key accomplishment for CureVac as the company prepares for multiple near-term corporate and clinical milestones that have the potential to significantly contribute to its leadership position in the field of mRNA,” said Ingmar Hoerr, PhD, the co-founder and CEO of CureVac, in a statement.
Senior Writer
As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.